2026 Interim report
Filed with HKEX · Stock code 2256 · · 97 pages · English
Summary by 6ix AI
The report indicates a commercial launch of their lead asset, pimicotinib, in China, alongside advancements in various clinical programs. Financially, the company reported a notable decrease in revenue compared to the previous year, primarily due to changes in licensing income. Despite the revenue drop, Abbisko maintains a strong financial position with substantial cash reserves to support ongoing innovation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Abbisko Cayman
- Voluntary announcement - abbisko therapeutics announces positive preliminary phase II results with lavengratinib (ABSK061) for the treatment of achondroplasia
- Poll results of the extraordinary general meeting held on September 17, 2026
- AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
- Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
- Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
Later from Abbisko Cayman
- Next Day Disclosure Returns
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Abbisko Cayman into a list and get an email when it puts out news.
Follow Abbisko Cayman